Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuya Sho

Showing results (91-100 of 120) with videos related to

Pageof 12
Sort By:
Abdominal Imaging|January 13, 2015
Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinomaSeiji Tsunematsu, Makoto Chuma, Toshiya Kamiyama, et al.
Journal of Gastroenterology and Hepatology|March 19, 2020
Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in JapanTakashi Kitagataya, Goki Suda, Kazunori Nagashima, et al.
Cancers|August 26, 2022
Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150Takuya Sho, Goki Suda, Yoshiya Yamamoto, et al.
Journal of Gastroenterology|February 20, 2019
Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infectionGoki Suda, Chitomi Hasebe, Masami Abe, et al.
Scientific Reports|January 17, 2020
Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitisKoji Ogawa, Takashi Kobayashi, Jun-Ichi Furukawa, et al.
The Journal of Infection|February 28, 2026
Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective studyGoki Suda, Masatsugu Ohara, Masaru Baba, et al.
Liver Cancer|June 16, 2023
Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab TreatmentShunichi Hosoda, Goki Suda, Takuya Sho, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 21, 2025
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World StudyFederica Lo Prinzi, Federico Rossari, Antonio De Rosa, et al.
Liver Cancer|January 2, 2023
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT StudyAndrea Casadei-Gardini, Margherita Rimini, Masatoshi Kudo, et al.
Journal of Medical Virology|January 4, 2023
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitisGoki Suda, Masaru Baba, Yoshiya Yamamoto, et al.
Pageof 12

Showing results (91-100 of 120) with videos related to

Sort By:
Pageof 12
Abdominal Imaging|January 13, 2015
Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinomaSeiji Tsunematsu, Makoto Chuma, Toshiya Kamiyama, et al.
Journal of Gastroenterology and Hepatology|March 19, 2020
Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in JapanTakashi Kitagataya, Goki Suda, Kazunori Nagashima, et al.
Cancers|August 26, 2022
Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150Takuya Sho, Goki Suda, Yoshiya Yamamoto, et al.
Journal of Gastroenterology|February 20, 2019
Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infectionGoki Suda, Chitomi Hasebe, Masami Abe, et al.
Scientific Reports|January 17, 2020
Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitisKoji Ogawa, Takashi Kobayashi, Jun-Ichi Furukawa, et al.
The Journal of Infection|February 28, 2026
Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective studyGoki Suda, Masatsugu Ohara, Masaru Baba, et al.
Liver Cancer|June 16, 2023
Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab TreatmentShunichi Hosoda, Goki Suda, Takuya Sho, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 21, 2025
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World StudyFederica Lo Prinzi, Federico Rossari, Antonio De Rosa, et al.
Liver Cancer|January 2, 2023
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT StudyAndrea Casadei-Gardini, Margherita Rimini, Masatoshi Kudo, et al.
Journal of Medical Virology|January 4, 2023
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitisGoki Suda, Masaru Baba, Yoshiya Yamamoto, et al.
Pageof 12